Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter

Didier Vandier, Olivier Rixe, François Besnard, Min Kim, Toshiki Rikiyama, Merrill Goldsmith, Michael Brenner, Alain Gouyette, Kenneth H Cowan

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Gene therapy using the herpes simplex virus thymidine kinase (HSV-TK) gene in combination with the drug ganciclovir (GCV) is a promising approach for the treatment of cancer-inducing gliomas, a tumor with a poor prognosis. In an attempt to limit the toxic effects on normal tissues, we constructed a recombinant adenoviral vector, Adgfa2TK, in which the HSV-TK gene is driven by the promoter for the gene encoding glial fibrillary acidic protein, an intermediate filament protein expressed primarily in astrocytes. Infection by Adgfa2TK of a glial cell line (C6) and a non-glial cell line (MDA-MB-231) revealed markedly increased expression of HSV-TK in glial cells as determined by Western blot. In comparison, high HSV-TK protein levels were produced in both cell lines after infection with a control virus, AdCMVTK, in which the constitutive cytomegalovirus viral promoter was used to direct HSV-TK expression. Infection of two glial cell lines (C6, U251) and two non-glial cell lines (HepG2, MDA-MB-231) with Adgfa2TK followed by GCV treatment revealed high toxicity in glial cell lines (50% growth inhibitory concentration: <2 μg/mL of GCV) with little or no toxicity (50% growth inhibitory concentration: >75 μg/mL) in the non-glial cell lines. In vivo, injection of Adgfa2TK into C6 tumors grown in nude mice followed by intraperitoneal GCV treatment significantly repressed tumor growth compared with the controls. Adgfa2TK may be useful for directing expression of the HSV-TK gene to gliomas.

Original languageEnglish (US)
Pages (from-to)1120-1126
Number of pages7
JournalCancer Gene Therapy
Volume7
Issue number8
DOIs
StatePublished - Jan 1 2000

Fingerprint

Thymidine Kinase
Glioma
Astrocytes
Simplexvirus
Cell Line
Neuroglia
Ganciclovir
Genes
Neoplasms
Infection
Intermediate Filament Proteins
Poisons
Glial Fibrillary Acidic Protein
Drug Combinations
Growth
In Vitro Techniques
Cytomegalovirus
Nude Mice
Genetic Therapy
Inhibitory Concentration 50

Keywords

  • Adenovirus
  • Gene therapy
  • Glial fibrillary acidic protein
  • Glioblastoma
  • Herpes simplex virus thymidine kinase gene

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. / Vandier, Didier; Rixe, Olivier; Besnard, François; Kim, Min; Rikiyama, Toshiki; Goldsmith, Merrill; Brenner, Michael; Gouyette, Alain; Cowan, Kenneth H.

In: Cancer Gene Therapy, Vol. 7, No. 8, 01.01.2000, p. 1120-1126.

Research output: Contribution to journalArticle

Vandier, D, Rixe, O, Besnard, F, Kim, M, Rikiyama, T, Goldsmith, M, Brenner, M, Gouyette, A & Cowan, KH 2000, 'Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter', Cancer Gene Therapy, vol. 7, no. 8, pp. 1120-1126. https://doi.org/10.1038/sj.cgt.7700211
Vandier, Didier ; Rixe, Olivier ; Besnard, François ; Kim, Min ; Rikiyama, Toshiki ; Goldsmith, Merrill ; Brenner, Michael ; Gouyette, Alain ; Cowan, Kenneth H. / Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. In: Cancer Gene Therapy. 2000 ; Vol. 7, No. 8. pp. 1120-1126.
@article{db7d6d9038ec42d9be8876ed7c7dfc90,
title = "Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter",
abstract = "Gene therapy using the herpes simplex virus thymidine kinase (HSV-TK) gene in combination with the drug ganciclovir (GCV) is a promising approach for the treatment of cancer-inducing gliomas, a tumor with a poor prognosis. In an attempt to limit the toxic effects on normal tissues, we constructed a recombinant adenoviral vector, Adgfa2TK, in which the HSV-TK gene is driven by the promoter for the gene encoding glial fibrillary acidic protein, an intermediate filament protein expressed primarily in astrocytes. Infection by Adgfa2TK of a glial cell line (C6) and a non-glial cell line (MDA-MB-231) revealed markedly increased expression of HSV-TK in glial cells as determined by Western blot. In comparison, high HSV-TK protein levels were produced in both cell lines after infection with a control virus, AdCMVTK, in which the constitutive cytomegalovirus viral promoter was used to direct HSV-TK expression. Infection of two glial cell lines (C6, U251) and two non-glial cell lines (HepG2, MDA-MB-231) with Adgfa2TK followed by GCV treatment revealed high toxicity in glial cell lines (50{\%} growth inhibitory concentration: <2 μg/mL of GCV) with little or no toxicity (50{\%} growth inhibitory concentration: >75 μg/mL) in the non-glial cell lines. In vivo, injection of Adgfa2TK into C6 tumors grown in nude mice followed by intraperitoneal GCV treatment significantly repressed tumor growth compared with the controls. Adgfa2TK may be useful for directing expression of the HSV-TK gene to gliomas.",
keywords = "Adenovirus, Gene therapy, Glial fibrillary acidic protein, Glioblastoma, Herpes simplex virus thymidine kinase gene",
author = "Didier Vandier and Olivier Rixe and Fran{\cc}ois Besnard and Min Kim and Toshiki Rikiyama and Merrill Goldsmith and Michael Brenner and Alain Gouyette and Cowan, {Kenneth H}",
year = "2000",
month = "1",
day = "1",
doi = "10.1038/sj.cgt.7700211",
language = "English (US)",
volume = "7",
pages = "1120--1126",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter

AU - Vandier, Didier

AU - Rixe, Olivier

AU - Besnard, François

AU - Kim, Min

AU - Rikiyama, Toshiki

AU - Goldsmith, Merrill

AU - Brenner, Michael

AU - Gouyette, Alain

AU - Cowan, Kenneth H

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Gene therapy using the herpes simplex virus thymidine kinase (HSV-TK) gene in combination with the drug ganciclovir (GCV) is a promising approach for the treatment of cancer-inducing gliomas, a tumor with a poor prognosis. In an attempt to limit the toxic effects on normal tissues, we constructed a recombinant adenoviral vector, Adgfa2TK, in which the HSV-TK gene is driven by the promoter for the gene encoding glial fibrillary acidic protein, an intermediate filament protein expressed primarily in astrocytes. Infection by Adgfa2TK of a glial cell line (C6) and a non-glial cell line (MDA-MB-231) revealed markedly increased expression of HSV-TK in glial cells as determined by Western blot. In comparison, high HSV-TK protein levels were produced in both cell lines after infection with a control virus, AdCMVTK, in which the constitutive cytomegalovirus viral promoter was used to direct HSV-TK expression. Infection of two glial cell lines (C6, U251) and two non-glial cell lines (HepG2, MDA-MB-231) with Adgfa2TK followed by GCV treatment revealed high toxicity in glial cell lines (50% growth inhibitory concentration: <2 μg/mL of GCV) with little or no toxicity (50% growth inhibitory concentration: >75 μg/mL) in the non-glial cell lines. In vivo, injection of Adgfa2TK into C6 tumors grown in nude mice followed by intraperitoneal GCV treatment significantly repressed tumor growth compared with the controls. Adgfa2TK may be useful for directing expression of the HSV-TK gene to gliomas.

AB - Gene therapy using the herpes simplex virus thymidine kinase (HSV-TK) gene in combination with the drug ganciclovir (GCV) is a promising approach for the treatment of cancer-inducing gliomas, a tumor with a poor prognosis. In an attempt to limit the toxic effects on normal tissues, we constructed a recombinant adenoviral vector, Adgfa2TK, in which the HSV-TK gene is driven by the promoter for the gene encoding glial fibrillary acidic protein, an intermediate filament protein expressed primarily in astrocytes. Infection by Adgfa2TK of a glial cell line (C6) and a non-glial cell line (MDA-MB-231) revealed markedly increased expression of HSV-TK in glial cells as determined by Western blot. In comparison, high HSV-TK protein levels were produced in both cell lines after infection with a control virus, AdCMVTK, in which the constitutive cytomegalovirus viral promoter was used to direct HSV-TK expression. Infection of two glial cell lines (C6, U251) and two non-glial cell lines (HepG2, MDA-MB-231) with Adgfa2TK followed by GCV treatment revealed high toxicity in glial cell lines (50% growth inhibitory concentration: <2 μg/mL of GCV) with little or no toxicity (50% growth inhibitory concentration: >75 μg/mL) in the non-glial cell lines. In vivo, injection of Adgfa2TK into C6 tumors grown in nude mice followed by intraperitoneal GCV treatment significantly repressed tumor growth compared with the controls. Adgfa2TK may be useful for directing expression of the HSV-TK gene to gliomas.

KW - Adenovirus

KW - Gene therapy

KW - Glial fibrillary acidic protein

KW - Glioblastoma

KW - Herpes simplex virus thymidine kinase gene

UR - http://www.scopus.com/inward/record.url?scp=0033841598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033841598&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700211

DO - 10.1038/sj.cgt.7700211

M3 - Article

C2 - 10975672

AN - SCOPUS:0033841598

VL - 7

SP - 1120

EP - 1126

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 8

ER -